PEGylated Multistimuli-Responsive Dendritic Prodrug-Based Nanoscale System for Enhanced Anticancer Activity

Area of Science:

• Biomaterials Science
• Nanotechnology
• Drug Delivery Systems

Background:

• Hydrophobic drugs often face challenges in systemic delivery due to poor solubility and rapid clearance.
• Developing advanced nanoscale systems is crucial for improving drug efficacy and reducing side effects.
• Dendritic copolymers offer unique structural properties for drug conjugation and controlled release.

Purpose of the Study:

• To develop a PEGylated multistimuli-responsive dendritic copolymer-doxorubicin (DOX) prodrug-based nanoscale system for hydrophobic drug delivery.
• To evaluate the in vivo pharmacokinetics, tumor accumulation, and therapeutic efficacy of the developed nanoscale system.
• To assess the potential of this system as an alternative to traditional chemotherapy for breast cancer.

Main Methods:

• Synthesis of a PEGylated dendritic copolymer-DOX prodrug nanoscale system.
• Characterization of nanoparticle size, surface charge, and drug loading.
• In vitro studies on drug release, cellular uptake, and apoptosis induction.
• In vivo pharmacokinetic studies, biodistribution analysis in mice, and antitumor efficacy evaluation in a 4T1 breast cancer model.

Main Results:

• The PEGylated system exhibited prolonged circulation (14.6 h half-life) and formed nanoparticles (approx. 150 nm) for enhanced endocytosis.
• DOX release was triggered by acidic endosomes/lysosomes, inducing mitochondrial dysfunction and apoptosis in vitro.
• Significant accumulation of the nanoscale system in tumor tissues was observed, with reduced toxicity to normal tissues.
• The system demonstrated superior antitumor efficacy in the 4T1 breast cancer model, achieving up to 86.5% tumor growth inhibition by inhibiting angiogenesis, proliferation, and inducing apoptosis.

Conclusions:

• The developed PEGylated multistimuli-responsive dendritic copolymer-DOX prodrug nanoscale system is a promising platform for hydrophobic drug delivery.
• This system offers improved pharmacokinetics, targeted tumor accumulation, and enhanced antitumor efficacy with reduced side effects.
• It represents a potential alternative to conventional chemotherapy for breast cancer treatment.